Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.

You may also be interested in...



Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix

Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.

Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix

Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.

Generic Exclusivity On Delisted Patents Upheld By Appeals Court

In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel